'Dyslipidemia' diaporamas de présentation

A therogenic D iabetic D yslipidemia ( ADD ) - Time to Relook & Evaluate Treatment Options

A therogenic D iabetic D yslipidemia ( ADD ) - Time to Relook & Evaluate Treatment Options. 14339_89. 3_85. K ey questions. How big is the challenge of Atherogenic Diabetic dyslipidemia (ADD ) in INDIA? Why diabetics are more prone to dyslipidemia?

874 views • 75 slides

986 views • 57 slides

MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION

MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION. 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. VASCULAR PROTECTION.

293 views • 26 slides

Diabetes

423 views • 24 slides

Exercise Prescription

Exercise Prescription. Cardiac Rehabilitation. WHY EXERCISE?. Hypertension Dyslipidemia Smoking Obesity Diabetes Stress. Unstable angina systolic/diastolic hypertension orthostatic drop > 20mm Hg with symptoms critical aortic stenosis acute systemic illness or fever uncompensated CHF

344 views • 10 slides

Dyslipidemia Therapeutics Market Share, Size, Growth, Industry Analysis and Forecast to 2024 - Hexa Research

Dyslipidemia is an interminable metabolic disorder, described by improper level of low thickness lipoprotein, high thickness lipoprotein, and triglycerides. The expanding demand and solutions of these medicines is offering lucrative growth opportunities for the dyslipidemia market.

134 views • 4 slides

(A) Patients with baseline NIHSS of 0 to 4

Figure e-1. Combined effects of intra/extracranial vascular occlusive lesion and leg weakness or extinction/inattention on unfavorable outcome. (A) Patients with baseline NIHSS of 0 to 4. p<0.001. p=0.001. Risk of an unfavorable outcome. p<0.001. - -. - +. + -. + +.

226 views • 1 slides